Chlamydia is a sexually transmitted infectious disease caused by the bacterium Chlamydia trachomatis. In the United States, it is the most commonly reported bacterial infection. Globally, it is the most common sexually transmitted infection. It causes an ocular infection called "trachoma," which is the leading infectious cause of blindness worldwide.
In females, the cervix is the anatomic site which most commonly infected. This can manifest as cervicitis, urethritis, pelvic inflammatory disease, perihepatitis, or proctitis. Chlamydial infections in women, especially if untreated, increase the risk of infertility and ectopic pregnancy, leading to high medical costs. There are also risks if a woman has an infection during pregnancy. Additionally, infants born vaginally to mothers infected with genital Chlamydia trachomatis may develop conjunctivitis and/or pneumonia.
In men, infection with Chlamydia trachomatis can lead to urethritis, epididymitis, prostatitis, proctitis, or reactive arthritis. Both men and women infected with C. trachomatis may also experience conjunctivitis, pharyngitis, and lymphogranuloma venereum. Lymphogranuloma venereum (LGV), caused by distinct serovars of Chlamydia trachomatis, is a less common disease characterized by enlarged lymph nodes or severe proctocolitis.
Chlamydia trachomatis is part of the chlamydophila genus. These bacteria are gram-negative, anaerobic, intracellular obligates that replicate within eukaryotic cells. C. trachomatis differentiates into 18 serovars (serologically variant strains) based on monoclonal antibody-based typing assays. These serovars correlate with multiple medical conditions as follows:
Serovars A, B, Ba, and C: Trachoma is a serious eye disease endemic in Africa and Asia that is characterized by chronic conjunctivitis and can lead to blindness
Serovars D-K: Genital tract infections, neonatal infections
Serovars L1-L3: Lymphogranuloma venereum (LGV), which correlates with genital ulcer disease in tropical countries
Urogenital chlamydia infections are the most commonly reported bacterial infections in the U.S and the most common cause of sexually transmitted infection in the world. The overall rate of urogenital infection amongst U.S. women is twice that among U.S. men, with a higher prevalence in women 15-24 years of age and a higher incidence in men between 20-24 years of age.
Chlamydia is unique among bacteria, having an infectious cycle and two developmental forms. These include the infectious form called the elementary body (EB) and the reticulate body (RB). The EB is metabolically inactive and is taken up by host cells. Within the host cell, the EB will differentiate into the metabolically active RB. The RB will then use host energy sources and amino acids to replicate and form new EB which can then infect additional cells. The target cells of C. trachomatis are the squamocolumnar epithelial cells of the endocervix and upper genital tract in women, and the conjunctiva, urethra, and rectum in both men and women.
The bacterium is transmitted through direct contact with infected tissue, including vaginal, anal or oral sex, and can even be passed from an infected mother to the newborn during childbirth.
Typical intracytoplasmic inclusions and free chlamydiae are identifiable in Giemsa-stained cell scrapings from the eye. Stained conjunctival scrapings are positive in 90% of infants with neonatal conjunctivitis, and 50% of adults with inclusion conjunctivitis. Cytology techniques can be used to evaluate endocervical scrapings, but the sensitivity and specificity are low.
C. trachomatis can lead to many urogenital infections including cervicitis, pelvic inflammatory disease, urethritis, epididymitis, prostatitis and lymphogranuloma venereum. Extragenital infections caused by C. trachomatis include conjunctivitis, perihepatitis, pharyngitis, reactive arthritis, and proctitis.
Most commonly, patients remain asymptomatic reservoirs of the disease. In the minority of patients that are symptomatic, clinical signs depend on the location of the infection. Below are the common signs and symptoms associated with C. trachomatis urogenital infections.
Among C. trachomatis infections, only trachoma is diagnosable on clinical grounds. Other chlamydial infections are associated with specific clinical syndromes but require laboratory confirmation. The gold standard for the diagnosis of urogenital chlamydia infections is nucleic acid amplification testing (NAAT). This test is run on either the vaginal swabs for women or first-catch urine for men. Testing can also be performed on endocervical or urethral swabs. Swabs should have a wire or plastic shaft; the tip should be dacron or rayon or a cytobrush. Other materials may inhibit Chlamydia trachomatis. Alternative and methods of testing include culture, rapid testing, serology, antigen detection, and genetic probes. If there is no testing available, treatment is recommended based on clinical presentation.
When patients present with suspected chlamydia, a workup for other STDs should be done. A complete blood count is necessary if PID is suspected. One may consider HIV, gonorrhea and syphilis testing. The sexual partner should be tested for chlamydia. A pregnancy test should be done as it is a contraindication to doxycycline therapy.
Cytology is often used in patients with conjunctivitis and ocular trachoma. Cultures are usually not done for chlamydia as the organism is difficult to grow in the laboratory. However, in patients with anal and rectal involvement, cultures are ideal as other tests are difficult to interpret.
The USPSTF recommends regular screening for chlamydia in all sexually active women because if left untreated, the infection is associated with PID, infertility and chronic pelvic pain. In males, the leucocyte esterase test in urine can be done and is diagnostic for gonorrhea or chlamydia in the absence of a UTI.
The goal of treatment is the prevention of complications associated with infection (e.g., PID, infertility), to decrease the risk of transmission, and the resolution of symptoms. Treatment for uncomplicated urogenital chlamydia infection is with azithromycin. Doxycycline is an alternative, but azithromycin is preferred as it is a single-dose therapy.
Chlamydial infection and gonococcal infections often coexist. In men, the driver behind co-treatment for urogenital gonococcal infection should be by detection of the organism on NAAT or gram stain. In women, the gram stain is less helpful due to the possibility of normal Neisseria species colonization within the vaginal flora. Therefore, co-treatment should be dependent on an assessment of individual patient risk and local prevalence rates.
Patients should have partners identified and tested. They should also be counseled on high-risk behaviors, avoid sexual activity for one week after initiating therapy, and should consider testing for HIV.
Verification of cure should occur either three weeks after treatment completion, and retesting should be performed at three months after treatment.
If symptoms persist after treatment, consider coinfection with a secondary bacterium or reinfection.
Follow up culture is not recommended in most people but may be considered in a pregnant female.
Because Chlamydia trachomatis can lead to a broad spectrum of clinical diseases or manifestations, the differential diagnosis of various presenting complaints is also broad. One should consider other etiologies that may affect each body area or organ systems and may manifest similarly.
Postcoital or Intermenstrual Bleeding:
Uncomplicated Genital Chlamydia:
The World Health Organization (WHO) recommendations for treatment of uncomplicated genital chlamydia infections are the following:
Anorectal Chlamydial infection:
In anorectal chlamydial infections, the WHO recommendation is oral doxycycline 100 mg twice daily for 7 days over oral azithromycin 1 g as a single dose.
Chlamydial infection in pregnancy:
WHO recommends the following for the treatment of chlamydial infection in pregnancy:
The WHO recommends the following for the treatment of lymphogranuloma venereum (LGV):
Oral erythromycin is the preferred treatment for both conjunctivitis and pneumonia in the neonate. Azithromycin is an acceptable alternative. Infants who fail an initial course of erythromycin are recommended to retreat with another fourteen-day course of erythromycin.
In neonates being treated for chlamydial infection, both azithromycin and erythromycin are associated with a risk of infantile hypertrophic pyloric stenosis. This is particularly a concern for infants two weeks old or younger. Parents and physicians should observe infants closely for any signs of intestinal obstruction.
Antibiotic treatment has a 95% effectiveness rate for first-time therapy. The prognosis is excellent with prompt initiation of treatment early and with the completion of the entire course of antibiotics. Although treatment failures with primary therapies are quite rare, relapse may occur. Reinfection is common, and is usually related to nontreatment of infected sexual partners or acquisition from a new partner. Death is rare but can be caused by progression to salpingitis and tubo-ovarian abscess with rupture and peritonitis. The most significant morbidity occurs with repetitive infection with chlamydiae, which leads to scarring of the fallopian tubes and subsequent sterility.
Pelvic inflammatory disease confers a risk of ectopic pregnancy in women of childbearing age. Inflammation and scarring of the upper genital tract may also affect fertility or lead to chronic pelvic pain. Chlamydial infection in pregnancy can also increase the risk of prelabor rupture of membranes (PROM), premature prelabor rupture of membranes (PPROM), and preterm delivery.
Asymptomatic infection with Chlamydia trachomatis is very common, whereas the consequences of undiagnosed or untreated infection can be far-reaching. It is for these reasons that screening is recommended. All pregnant women are recommended to be screened for C. trachomatis. All sexually active females younger than 25 should be screened annually. Women older than 25 should be screened if they have risk factors for sexually transmitted infections. Risk factors include sexual partners with multiple concurrent partners, new or multiple sexual partners, inconsistent use of condoms if the relationship is not monogamous, exchanging sex for money or drugs, or previous/coexisting STI. Men who have sex with men should also be screened for chlamydial infection. In individuals with HIV, screening should be done at the initial presentation and annually. For individuals entering a correctional facility, it is recommended to screen for chlamydia in women 35 years old or younger and men thirty years old or younger.
In the United States, C. trachomatis is considered a notifiable infection. Local and state laws regarding disease reporting apply. Sexual partners should be notified, examined, and treated if an STI is found in the index patient. Expedited partner therapy may also be available in certain settings. Expedited partner therapy allows providers to prescribe antibiotics to sexual contacts without establishing a physician-patient relationship.
Patients should be educated regarding the potentially serious consequences of chlamydia infections and the importance of screening. Patients also should be educated that screening can often be performed non-invasively with urine samples. Educated patients may then be agreeable to screening when they would otherwise hesitate out of fear of an uncomfortable exam.
In the United States and other developed countries, the prevention of sexually transmitted genital infections and complications mainly focuses on screening and treating nonpregnant sexually active women aged 25 years or younger on an annual basis. Screening for pregnant women is recommended and screening and treatment of women over 25 years of age are recommendations if there are identifiable risk factors, such as new or multiple sexual partners. Screening of young men in high-risk settings (sexually transmitted infection and adolescent clinics, correctional facilities) should be a consideration if resources allow. Urine or endocervical NAAT are the recommended screening tests. The partner should be screened and treated at the same time.
Healthcare workers and nurse practitioners should educate patients on the importance of using a condom during sex, practicing safe sex or abstaining from sexual activity to prevent chlamydia.
The prognosis is excellent with prompt initiation of treatment early and with the completion of the entire course of antibiotics; antibiotic treatment is 95% effective for first-time therapy.
No vaccine is currently available for either trachoma or chlamydial genital infections.
The healthcare team including clinicians, nurses, and pharmacists must work together to educate the patient on methods to avoid exposure and the importance of completing treatment. This will result in decreased incidence and improve outcomes. [Level 5]
|||Owusu-Edusei K Jr,Chesson HW,Gift TL,Tao G,Mahajan R,Ocfemia MC,Kent CK, The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sexually transmitted diseases. 2013 Mar [PubMed PMID: 23403600]|
|||Mabey D,Peeling RW, Lymphogranuloma venereum. Sexually transmitted infections. 2002 Apr [PubMed PMID: 12081191]|
|||Morré SA,Rozendaal L,van Valkengoed IG,Boeke AJ,van Voorst Vader PC,Schirm J,de Blok S,van Den Hoek JA,van Doornum GJ,Meijer CJ,van Den Brule AJ, Urogenital Chlamydia trachomatis serovars in men and women with a symptomatic or asymptomatic infection: an association with clinical manifestations? Journal of clinical microbiology. 2000 Jun [PubMed PMID: 10834991]|
|||Mordhorst CH,Dawson C, Sequelae of neonatal inclusion conjunctivitis and associated disease in parents. American journal of ophthalmology. 1971 Apr [PubMed PMID: 4928532]|
|||Detels R,Green AM,Klausner JD,Katzenstein D,Gaydos C,Handsfield H,Pequegnat W,Mayer K,Hartwell TD,Quinn TC, The incidence and correlates of symptomatic and asymptomatic Chlamydia trachomatis and Neisseria gonorrhoeae infections in selected populations in five countries. Sexually transmitted diseases. 2011 Jun [PubMed PMID: 22256336]|
|||Pelvic inflammatory disease. American family physician. 2012 Apr 15; [PubMed PMID: 22534389]|
|||Kobayashi S,Kida I, Reactive arthritis: recent advances and clinical manifestations. Internal medicine (Tokyo, Japan). 2005 May; [PubMed PMID: 15942084]|
|||Schachter J,Grossman M,Sweet RL,Holt J,Jordan C,Bishop E, Prospective study of perinatal transmission of Chlamydia trachomatis. JAMA. 1986 Jun 27; [PubMed PMID: 3712696]|
|||Tipple MA,Beem MO,Saxon EM, Clinical characteristics of the afebrile pneumonia associated with Chlamydia trachomatis infection in infants less than 6 months of age. Pediatrics. 1979 Feb; [PubMed PMID: 440806]|
|||Rours GI,Duijts L,Moll HA,Arends LR,de Groot R,Jaddoe VW,Hofman A,Steegers EA,Mackenbach JP,Ott A,Willemse HF,van der Zwaan EA,Verkooijen RP,Verbrugh HA, Chlamydia trachomatis infection during pregnancy associated with preterm delivery: a population-based prospective cohort study. European journal of epidemiology. 2011 Jun; [PubMed PMID: 21538042]|